Thymosin beta-4 news and clinical trials

Researchers mapping radiation-induced brain injury in mice discovered that the blood-cerebrospinal fluid barrier is compromised during the early-delayed phase following irradiation. This disruption is caused by the depletion of a radiosensitive Tmsb4x-positive epithelial cell population.

Researchers identified that craniofacial involvement in extranodal diffuse large B-cell lymphoma is an independent adverse prognostic factor for survival. Patients with this involvement showed more frequent mutations in MYD88, TMSB4X, and PCLO.

ReGenTree, LLC completed a phase 3 clinical trial involving 700 participants to assess the safety and efficacy of RGN-259 ophthalmic solutions for dry eye syndrome. Results were posted on August 28, 2026.

A narrative review summarized the current evidence on regenerative peptides used for chronic pain management. The authors concluded that clinical evidence in humans remains limited and most of these therapies currently lack FDA approval.

Researchers demonstrated that recombinant human thymosin beta-4 improves survival and reduces intestinal fibrosis in mice with colitis by suppressing mineralocorticoid receptor signaling. The study notes that TMSB4X is typically downregulated in colonic tissues of IBD patients.

A scoping review concluded that claims regarding peptide supplements for musculoskeletal recovery remain unsubstantiated by current human trials. Authors warned of potential risks including cardiovascular complications.

Researchers investigated TMSB4X in T-cell acute lymphoblastic leukemia cells. They found that TMSB4X promotes cell proliferation and metastasis by regulating the Wnt/beta-catenin signaling pathway.

In a rat study, researchers evaluated the effects of BPC-157 and TB-500 on Achilles tendon healing. Both treatments were associated with improved histopathological parameters and extracellular matrix organization, though the combination of peptides did not provide additional benefits.

The HOMAGE trial analyzed urinary peptides in 268 patients at risk of heart failure to understand exercise intolerance. Researchers identified 11 non-collagen proteins, including TMSB4X, and 4 collagen-derived proteins associated with reduced exercise capacity.

New paper in iScience: Spatial transcriptomic analysis reveals spatial features in human Stanford type A aortic dissection.

Proteomic analysis of plasma from patients with diabetic foot syndrome identified a coordinated alteration in circulating damage-associated molecular patterns. The study observed that thymosin beta-4 was among the stress-associated proteins with differential abundance in these patients.

A study using electric cell-substrate impedance sensing technology analyzed the effects of ciprofloxacin on corneal epithelial cells. Researchers found that ciprofloxacin caused concentration-dependent cytotoxic effects and altered apoptotic signaling that thymosin beta-4 could not fully mitigate.

A study in Bioengineering & Translational Medicine developed a thiol-site-specific PEGylated thymosin beta-4 prodrug, PEG-rTβ4, to address druggability challenges. Testing indicated that this modified protein effectively relieves myocardial remodeling and improves cardiac function in vivo.

A narrative review explored the use of supplements, including collagen, BPC-157, and thymosin-beta 4 and 500, in Masters athletes and adults over 55. The review aims to examine their impact on performance and musculoskeletal health in this specific population.

Researchers constructed a 9-gene prognostic signature for colorectal cancer, which includes TMSB4X, to stratify patient risk and therapy sensitivity. Patients with a high risk score showed significantly worse overall survival and an immunosuppressive tumor microenvironment.

Researchers tested adjunctive thymosin beta-4 (Tβ4) treatment in mice with bacterial keratitis. They found that combining Tβ4 with ciprofloxacin significantly enhanced corneal nerve regeneration and restored visual function compared to monotherapies.

Researchers conducted a clinical trial involving UVB irradiation on healthy donors and MS patients. The study revealed that MS patients have a dysfunctional immune regulation axis, evidenced by blunted immune cell translation from skin to blood compared to healthy donors.

Researchers mapped gene expression changes in the mouse dentate gyrus following perforant path transection. Results showed that Tmsb4x, alongside other vesicle and actin regulators, was upregulated as part of the postsynaptic and dendritic membrane remodeling response.

An Integrative Medicine review evaluated the use of peptides for thyroid disorders, finding that current evidence for agents like BPC-157 and thymosin is largely limited to preclinical studies and exploratory reports rather than large randomized trials.

Researchers analyzed the role of TMSB4X in TIM3-induced CD8+ T cell exhaustion in diffuse large B-cell lymphoma. They found that decreased TMSB4X expression correlates with epigenetic dysregulation, poor prognosis, and inferior chemotherapy response.

Beijing Northland Biotech Co., Ltd. registered a phase IIc trial to evaluate the safety and efficacy of recombinant human thymosin beta 4 injection in 189 patients who have experienced a serious heart attack. The study will measure permanent heart muscle damage 90 days after treatment.

Researchers identified four mitophagy key genes-AW112010, Igfbp7, Tmsb4x, and Ost4-as potential biomarkers for immune checkpoint inhibitor-related myocarditis. These genes showed significantly higher expression levels in a myocarditis mouse model compared to a normal group.

Researchers published a review of approved and unapproved peptide therapies used in sports medicine. They found that while unapproved peptides often show potential for tissue repair in animal models, human safety data remain scarce and carry a risk of serious harm.

Hudson Biotech registered a phase 1/2 trial to evaluate the safety and tolerability of TB-500 in 80 adults with stable atherosclerotic cardiovascular disease. The study aims to explore cardiovascular biomarkers and vascular function.

Researchers compared the secretome of BRAF/MEK inhibitor-resistant melanoma cells to nonresistant cells. They found that resistant cells secrete higher levels of proteins, including thymosin beta-4, which may promote a pro-tumor microenvironment.

Researchers developed a machine learning model using extracellular vesicle-derived RNA to diagnose hepatocellular carcinoma. The study identified a panel of ten diagnostic mRNAs, including TMSB4X, which achieved an AUC of 0.8877 in testing.

A review published in Peptides synthesizes current evidence on Thymosin beta 4 (Tβ4) and its metabolite Ac-SDKP as mediators of renal injury and repair. The authors evaluate Tβ4's renoprotective efficacy across kidney injury models and discuss future translational opportunities.

Researchers analyzed gene expression in Kazakh horse testes before and after sexual maturity using transcriptome sequencing. The study identified 3054 differentially expressed genes, including TMSB4X, which are involved in pathways such as PI3K-Akt signaling and testicular development.

A study analyzing glioma multi-omics data identified the gene TMSB4X, along with RAN and others, as a core lactylation-related gene. High expression of RAN was significantly correlated with poor patient prognosis, and knockdown of this gene inhibited glioma cell invasion and proliferation.

Researchers demonstrated that the import factor importin 9 (IPO9) binds directly to monomeric actin, and that cofilin competitively inhibits this interaction. This finding contradicts the previous model where cofilin and IPO9 work together to transport actin into the nucleus.

Researchers mapped neuronal adaptation to intracortical implants in rats and identified 22 neuronal subpopulations. The study found that three injury-responsive neuronal clusters upregulate Tmsb4x during the acute phase following electrode implantation.

A study profiling hippocampal neuronal loss in mice post-mild traumatic brain injury identified ferroptosis as a dominant cell-death program. Researchers found that the gene Tmsb4x protects hippocampal neurons and improves motor and cognitive performance after injury.

A Cochrane systematic review of seven randomized controlled trials involving 494 participants examined medical and surgical interventions for neurotrophic keratopathy. The review aims to assess the efficacy and safety of current treatments for corneal nerve alterations and epithelial healing.